Bristol Myers Squibb reports positive phase 3 results for oral multiple myeloma therapy

The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen

FDA nod to groundbreaking combo therapy for relapsed multiple myeloma

This new treatment option can redefine how we approach RRMM treatment by giving healthcare providers a regimen with improvement in PFS and OS and a well-characterized safety profile

Evogene narrows focus to AI-driven molecule discovery after major strategic overhaul

Evogene said ChemPass AI was significantly expanded during 2025 through internal development and collaborations with Google Cloud

Merck delivers resilient 2025 performance despite global headwinds

Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results

Ind-Swift earns EcoVadis silver medal for sustainability excellence

The Silver Medal recognizes strong performance across sustainability, ethics, environment, labour & human rights, and responsible procurement

MGM Hospitals deliver life-saving CAR-T therapy to elderly cancer patients in Chennai

A next-generation, cell-based immunotherapy, CAR-T therapy engineers a patient’s own immune cells to detect and destroy cancer

Rapid medical weight loss fuels surge in facial aesthetics, Allergan data shows

Recent data reveal that patients undergoing MWL are entering aesthetic practices with unique needs tied to facial structure and skin quality

Esperion to acquire Corstasis, gaining first FDA-approved nasal spray Diuretic

Theravance Biopharma winds down Ampreloxetine programme after Phase 3 miss

AbbVie’s Risankizumab shows strong results in hard-to-treat Crohn’s disease patients

This study evaluated a difficult-to-treat Crohn's disease patient population